Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice The study results demonstrate ...
SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...
A new study from IIT Bombay, published in the Journal of the American Chemical Society, has uncovered a surprising player in the progression of type 2 diabetes: collagen. The very protein that ...
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback